Product Description
An RNA-based compound to prevent inflammatory lung damage in COVID-19 patients based on its unique macrophage targeting technology. The detrimental tissue damage occurs particularly in a severe course of COVID-19. The Federal Minister of Education and Research (BMBF) Stark-Watzinger announced rnatics as one of three winners of the national competition for new COVID-19 drugs and is supporting the further development of the rnatics drug with € 7 million euros. The therapy is expected to be efficacious in current and future mutations of SARS-CoV2. (Sourced from: https://rnatics.com/rnatics-granted-e-7-million-for-the-clinical-development-of-a-new-covid-19-drug/)
Mechanisms of Action: miR-21 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: RNATICS GmbH
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AMIR-21 | P1 |
Recruiting |
Healthy Volunteers |
2026-01-01 |